Abraxane Trial Doubles Surviving Patients
Australian biopharmaceutical company Specialised Therapeutics Australia announces that a Phase 3 clinical trial of breast cancer drug Abraxane (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.
The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) investigation involved 861 treatment naïve patients internationally.
Researchers found those patients treated with Abraxane plus gemcitabine had a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].
Moreover, Abraxane plus gemcitabine demonstrated a 59% increase in one-year survival (35% vs. 22%, p=0.0002) and demonstrated double the rate of survival at two years (9% vs. 4%, p=0.02) as compared to gemcitabine alone.
Abraxane plus gemcitabine also demonstrated statistically significant improvements in key secondary endpoints compared to gemcitabine alone, including a 31% reduction in the risk of progression or death with a median progression-free survival (PFS) of 5.5 vs. 3.7 months (HR 0.69, P=0.000024) and an overall response rate (ORR) of 23% compared to 7% (response rate ratio of 3.19, p=1.1 x 10-10). Another endpoint assessed included time to treatment failure, which was significantly improved with the Abraxane combination compared to gemcitabine alone [(median 5.1 vs. 3.6 months) (HR 0.70, P<0.0001)].
“The past few decades have brought us very few treatment advances for patients with advanced pancreatic cancer, which is both deadly and incredibly difficult to treat with success,” said Daniel D. Von Hoff, MD, FACP, Lead Principal Investigator of the MPACT study and Chief Scientific Officer for Scottsdale Healthcare’s Virginia G. Piper Cancer Centre Clinical Trials and Physician-In-Chief for TGen. “The fact that Abraxane plus gemcitabine demonstrated an overall survival benefit, and also did so at one and two years, is a significant step forward in offering potential new hope for our patients.”
Professor John Zalcberg, Chief Medical Officer and Executive Director of Cancer Medicine at the Peter MacCallum Cancer Centre in Melbourne, said the evidence strongly supported using Abraxane in combination with gemcitabine as a new standard of care to treat appropriate patients, many of whom were not diagnosed until the disease was metastatic.
While acknowledging that this advance could not be seen as a cure for pancreatic cancer, Professor Zalcberg said the 59% increase in the number of patients who lived beyond 12 months was very encouraging.
“We are extremely encouraged by the results of this study involving Abraxane and regard this outcome as a significant breakthrough in terms of the future management of this disease,” he said.
“In addition to treating women with metastatic breast cancer with Abraxane in the appropriate setting, we look forward to its approval in Australia for treating patients with advanced pancreatic cancer.”
Specialised Therapeutics Australia (STA) Chief Executive Officer Mr. Carlo Montagner said the positive data paved the way for Australian patients with advanced pancreatic cancer to access more effective treatment options.
He commented: “In Australia, pancreatic cancer is the fourth most common cause of death from cancer for both men and women2 and very few treatment options exist for this group of patients. We are extremely pleased to demonstrate that Abraxane is capable of prolonging survival for patients with advanced pancreatic cancer and we hope to have Abraxane approved by the Australian Therapeutic Goods Administration (TGA) in the latter half of 2014.”
The most common grade ≥ 3 treatment-related adverse events in the study for Abraxane plus gemcitabine vs. gemcitabine alone were neutropenia (38% vs. 27%), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). In the Abraxane plus gemcitabine arm, the median time to neuropathy improvement was 29 days. There was no difference in serious life threatening toxicity (4% in each arm).
These results are from an investigational study. Abraxane is not approved for the treatment of advanced pancreatic cancer. Following TGA review and approval, STA will seek to have Abraxane included on the Pharmaceutical Benefits Scheme (PBS) for the reimbursement of Abraxane for advanced pancreatic cancer.
Date: January 22, 2013
Source: Specialised Therapeutics Australia